During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of ...

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in ...

FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing ...

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations for treatment selection.

New 5-year data reveals cemiplimab plus chemotherapy significantly enhances survival rates for advanced non-small cell lung cancer patients.

A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in advanced clear cell ...

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent ...

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte ...

Neoadjuvant darovasertib elicited strong antitumor activity, reduced simulated radiation doses, and lowered the risk of ...

Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating ...

Promising results emerge from a clinical trial combining IDE397 and sacituzumab govitecan for treating MTAP-deleted ...